TNXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tonix Pharmaceuticals Holding Corp (TNXP) is not a strong buy for a beginner, long-term investor at this moment. While there are some positive catalysts such as insider buying and revenue growth, the stock's technical indicators, options sentiment, and financial performance suggest caution. The lack of strong trading signals and the company's negative net income and EPS trends further support a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), signaling a weak overall trend. The stock is trading near its resistance level (R1: 14.257), which could limit further upside in the short term.
Gross margin also improved significantly, up 48.34% YoY to 80.37.
The company's net income remains negative (-$46.91M), and EPS has dropped significantly (-59.67% YoY). There is no recent news or event-driven catalyst to drive the stock higher. Options sentiment is bearish, and the stock's technical indicators show limited upward momentum.
In Q4 2025, revenue increased by 108.75% YoY to $5.39M, and gross margin improved to 80.37%. However, net income remains negative at -$46.91M, and EPS dropped to -3.96, down 59.67% YoY. While revenue growth is promising, the company is still unprofitable.
No recent analyst ratings or price target changes are available for TNXP.
